Causes and Clinical Impact of Loss to Follow-Up in Patients with Proliferative Diabetic Retinopathy
Purpose. This study determined the clinical impact and causes of loss to follow-up (LTFU) from the patients’ perspective in individuals with proliferative diabetic retinopathy (PDR) who received panretinal photocoagulation (PRP) and/or intravitreal injections (IVIs) of antivascular endothelial growt...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | Journal of Ophthalmology |
| Online Access: | http://dx.doi.org/10.1155/2020/7691724 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832551224030789632 |
|---|---|
| author | Hazem Abdelmotaal Walid Ibrahim Mohamed Sharaf Khaled Abdelazeem |
| author_facet | Hazem Abdelmotaal Walid Ibrahim Mohamed Sharaf Khaled Abdelazeem |
| author_sort | Hazem Abdelmotaal |
| collection | DOAJ |
| description | Purpose. This study determined the clinical impact and causes of loss to follow-up (LTFU) from the patients’ perspective in individuals with proliferative diabetic retinopathy (PDR) who received panretinal photocoagulation (PRP) and/or intravitreal injections (IVIs) of antivascular endothelial growth factor (VEGF). Methods. This prospective cohort study included 467 patients with PDR who received PRP and/or IVIs of anti-VEGF between May 2013 and June 2018. LTFU was defined as missing any follow-up visit for any interval exceeding 6 months, provided that patients eventually resumed care. Main outcome measures include rates and causes of LTFU. Results. A total of 391 patients (83.7%) were followed up, and 76 patients (16.3%) were LTFU over the study period. Rates of LTFU decreased with age (P=0.005). Questionnaire analysis conducted for patients’ LTFU showed a significant positive correlation between best corrected visual activity (BCVA) loss and patient’s lack of trust and satisfaction with treatment (rs = 0.458, P<0.001). There was also a significant positive correlation between treatment unaffordability and number of IVIs of anti-VEGF (rs = 0.55, P<0.001) and lack of social support and age (rs = 0.39, P<0.001). Conclusions. LTFU threatens vision in PDR patients receiving PRP and/or IVIs of anti-VEGF. Possibly, patient-specific LTFU causes should be addressed before treatment in order to minimize the risk of LTFU. The clinical trial is registered with NCT04018326 (trial registration: ClinicalTrials.gov Identifier: NCT04018326, 10th of July 2019 “Retrospectively registered”). |
| format | Article |
| id | doaj-art-e8ffdd665335416ebe4e6af689cb57ff |
| institution | Kabale University |
| issn | 2090-004X 2090-0058 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Ophthalmology |
| spelling | doaj-art-e8ffdd665335416ebe4e6af689cb57ff2025-02-03T06:04:38ZengWileyJournal of Ophthalmology2090-004X2090-00582020-01-01202010.1155/2020/76917247691724Causes and Clinical Impact of Loss to Follow-Up in Patients with Proliferative Diabetic RetinopathyHazem Abdelmotaal0Walid Ibrahim1Mohamed Sharaf2Khaled Abdelazeem3Department of Ophthalmology, Faculty of Medicine, Assiut University, Assiut, EgyptDepartment of Ophthalmology, Faculty of Medicine, Assiut University, Assiut, EgyptDepartment of Ophthalmology, Faculty of Medicine, Assiut University, Assiut, EgyptDepartment of Ophthalmology, Faculty of Medicine, Assiut University, Assiut, EgyptPurpose. This study determined the clinical impact and causes of loss to follow-up (LTFU) from the patients’ perspective in individuals with proliferative diabetic retinopathy (PDR) who received panretinal photocoagulation (PRP) and/or intravitreal injections (IVIs) of antivascular endothelial growth factor (VEGF). Methods. This prospective cohort study included 467 patients with PDR who received PRP and/or IVIs of anti-VEGF between May 2013 and June 2018. LTFU was defined as missing any follow-up visit for any interval exceeding 6 months, provided that patients eventually resumed care. Main outcome measures include rates and causes of LTFU. Results. A total of 391 patients (83.7%) were followed up, and 76 patients (16.3%) were LTFU over the study period. Rates of LTFU decreased with age (P=0.005). Questionnaire analysis conducted for patients’ LTFU showed a significant positive correlation between best corrected visual activity (BCVA) loss and patient’s lack of trust and satisfaction with treatment (rs = 0.458, P<0.001). There was also a significant positive correlation between treatment unaffordability and number of IVIs of anti-VEGF (rs = 0.55, P<0.001) and lack of social support and age (rs = 0.39, P<0.001). Conclusions. LTFU threatens vision in PDR patients receiving PRP and/or IVIs of anti-VEGF. Possibly, patient-specific LTFU causes should be addressed before treatment in order to minimize the risk of LTFU. The clinical trial is registered with NCT04018326 (trial registration: ClinicalTrials.gov Identifier: NCT04018326, 10th of July 2019 “Retrospectively registered”).http://dx.doi.org/10.1155/2020/7691724 |
| spellingShingle | Hazem Abdelmotaal Walid Ibrahim Mohamed Sharaf Khaled Abdelazeem Causes and Clinical Impact of Loss to Follow-Up in Patients with Proliferative Diabetic Retinopathy Journal of Ophthalmology |
| title | Causes and Clinical Impact of Loss to Follow-Up in Patients with Proliferative Diabetic Retinopathy |
| title_full | Causes and Clinical Impact of Loss to Follow-Up in Patients with Proliferative Diabetic Retinopathy |
| title_fullStr | Causes and Clinical Impact of Loss to Follow-Up in Patients with Proliferative Diabetic Retinopathy |
| title_full_unstemmed | Causes and Clinical Impact of Loss to Follow-Up in Patients with Proliferative Diabetic Retinopathy |
| title_short | Causes and Clinical Impact of Loss to Follow-Up in Patients with Proliferative Diabetic Retinopathy |
| title_sort | causes and clinical impact of loss to follow up in patients with proliferative diabetic retinopathy |
| url | http://dx.doi.org/10.1155/2020/7691724 |
| work_keys_str_mv | AT hazemabdelmotaal causesandclinicalimpactoflosstofollowupinpatientswithproliferativediabeticretinopathy AT walidibrahim causesandclinicalimpactoflosstofollowupinpatientswithproliferativediabeticretinopathy AT mohamedsharaf causesandclinicalimpactoflosstofollowupinpatientswithproliferativediabeticretinopathy AT khaledabdelazeem causesandclinicalimpactoflosstofollowupinpatientswithproliferativediabeticretinopathy |